Real-world study examines caplacizumab for aTTP: better treatment on the horizon?
NCT ID NCT04985318
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at how doctors in Germany prescribed caplacizumab (Cablivi) for acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood clotting disorder. Researchers will analyze data from 350 patients to see how well the drug works outside of clinical trials and to find ways to improve treatment plans. The goal is to develop better guidelines that improve patient outcomes and reduce healthcare costs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- caplacizumab (Cablivi)
- What this could lead to
- If successful, this study could help doctors use caplacizumab more effectively, leading to better outcomes and lower treatment costs for people with aTTP.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients, and the drug's known risks (e.g., bleeding) remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 350 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2021
- Expected to finish
-
Dec 2034
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Male or female subjects with confirmed diagnosis of an acute episode of aquired thrombotic thrombocytopenic purpura, who have been treated with one dose of caplacizumab.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic purpura * Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.) * Male or female patients ≥ 18 years of age * signed written informed consent Exclusion Criteria: * Hereditary thrombotic thrombocytopenic purpura * disability to give informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acquired thrombotic thrombocytopenic purpura are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Cologne
Cologne, 50937, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.